# Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer

> **NCT00102375** · PHASE3 · COMPLETED · sponsor: **AGO Study Group** · enrollment: 900 (—)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT00102375
- **Lead sponsor:** AGO Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 900 (—)
- **Last updated:** 2006-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102375, "Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00102375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*